Use of Glucagon-Like Peptide-1 Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), known for their role in managing type 2 diabetes and obesity, show potential benefits in treating various dermatologic conditions. This systematic review highlights clinical improvements in conditions such as psoriasis, hidradenitis suppurativa, HAIR-AN syndrome, Hailey-Hailey disease, acne keloidalis nuchae, folliculitis decalvans, androgenic alopecia, and localized linear scleroderma, as observed in controlled trials, cohort studies, and case reports. The review discusses possible mechanisms, including immunologic, metabolic, and barrier-modulating pathways, suggesting that GLP-1RAs could be a promising therapeutic option in dermatology, though larger, prospective studies are needed for confirmation.